PMC:7417114 / 10434-11370 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T57","span":{"begin":0,"end":7},"obj":"Body_part"},{"id":"T58","span":{"begin":395,"end":403},"obj":"Body_part"}],"attributes":[{"id":"A57","pred":"fma_id","subj":"T57","obj":"http://purl.org/sig/ont/fma/fma67257"},{"id":"A58","pred":"fma_id","subj":"T58","obj":"http://purl.org/sig/ont/fma/fma84050"}],"text":"Protein kinases have become an exceptionally important group of drug targets, accounting for 20-30% of the drug discovery programs of major pharmaceutical companies and are thus an opportune target. Many kinase inhibitors that have pharmacologic effects that may be beneficial in ameliorating the severe and potentially life-threatening symptoms of COVID-19, such as anti-inflammatory activity, cytokine suppression, and antifibrotic activity, are already approved. Ideally, one kinase inhibitor with optimal pharmacokinetic properties could be repurposed as a dual function therapeutic that could reduce infection through direct viral targeting and could also provide clinical benefit by suppressing disease symptoms. Alternatively, kinase inhibitors could be tested in combination with antiviral agents or other targeted therapies that show promise in clinical trials for COVID-19 to achieve greater efficacy than any one agent alone."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T110","span":{"begin":349,"end":357},"obj":"Disease"},{"id":"T111","span":{"begin":605,"end":614},"obj":"Disease"},{"id":"T112","span":{"begin":874,"end":882},"obj":"Disease"}],"attributes":[{"id":"A110","pred":"mondo_id","subj":"T110","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A111","pred":"mondo_id","subj":"T111","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A112","pred":"mondo_id","subj":"T112","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"Protein kinases have become an exceptionally important group of drug targets, accounting for 20-30% of the drug discovery programs of major pharmaceutical companies and are thus an opportune target. Many kinase inhibitors that have pharmacologic effects that may be beneficial in ameliorating the severe and potentially life-threatening symptoms of COVID-19, such as anti-inflammatory activity, cytokine suppression, and antifibrotic activity, are already approved. Ideally, one kinase inhibitor with optimal pharmacokinetic properties could be repurposed as a dual function therapeutic that could reduce infection through direct viral targeting and could also provide clinical benefit by suppressing disease symptoms. Alternatively, kinase inhibitors could be tested in combination with antiviral agents or other targeted therapies that show promise in clinical trials for COVID-19 to achieve greater efficacy than any one agent alone."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T114","span":{"begin":385,"end":393},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T115","span":{"begin":434,"end":442},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T116","span":{"begin":559,"end":560},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T117","span":{"begin":761,"end":767},"obj":"http://purl.obolibrary.org/obo/UBERON_0000473"}],"text":"Protein kinases have become an exceptionally important group of drug targets, accounting for 20-30% of the drug discovery programs of major pharmaceutical companies and are thus an opportune target. Many kinase inhibitors that have pharmacologic effects that may be beneficial in ameliorating the severe and potentially life-threatening symptoms of COVID-19, such as anti-inflammatory activity, cytokine suppression, and antifibrotic activity, are already approved. Ideally, one kinase inhibitor with optimal pharmacokinetic properties could be repurposed as a dual function therapeutic that could reduce infection through direct viral targeting and could also provide clinical benefit by suppressing disease symptoms. Alternatively, kinase inhibitors could be tested in combination with antiviral agents or other targeted therapies that show promise in clinical trials for COVID-19 to achieve greater efficacy than any one agent alone."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T80","span":{"begin":0,"end":7},"obj":"Chemical"},{"id":"T81","span":{"begin":55,"end":60},"obj":"Chemical"},{"id":"T82","span":{"begin":64,"end":68},"obj":"Chemical"},{"id":"T83","span":{"begin":107,"end":111},"obj":"Chemical"},{"id":"T84","span":{"begin":140,"end":154},"obj":"Chemical"},{"id":"T85","span":{"begin":211,"end":221},"obj":"Chemical"},{"id":"T86","span":{"begin":486,"end":495},"obj":"Chemical"},{"id":"T87","span":{"begin":741,"end":751},"obj":"Chemical"},{"id":"T88","span":{"begin":788,"end":804},"obj":"Chemical"}],"attributes":[{"id":"A80","pred":"chebi_id","subj":"T80","obj":"http://purl.obolibrary.org/obo/CHEBI_16541"},{"id":"A81","pred":"chebi_id","subj":"T81","obj":"http://purl.obolibrary.org/obo/CHEBI_24433"},{"id":"A82","pred":"chebi_id","subj":"T82","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A83","pred":"chebi_id","subj":"T83","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A84","pred":"chebi_id","subj":"T84","obj":"http://purl.obolibrary.org/obo/CHEBI_52217"},{"id":"A85","pred":"chebi_id","subj":"T85","obj":"http://purl.obolibrary.org/obo/CHEBI_35222"},{"id":"A86","pred":"chebi_id","subj":"T86","obj":"http://purl.obolibrary.org/obo/CHEBI_35222"},{"id":"A87","pred":"chebi_id","subj":"T87","obj":"http://purl.obolibrary.org/obo/CHEBI_35222"},{"id":"A88","pred":"chebi_id","subj":"T88","obj":"http://purl.obolibrary.org/obo/CHEBI_22587"}],"text":"Protein kinases have become an exceptionally important group of drug targets, accounting for 20-30% of the drug discovery programs of major pharmaceutical companies and are thus an opportune target. Many kinase inhibitors that have pharmacologic effects that may be beneficial in ameliorating the severe and potentially life-threatening symptoms of COVID-19, such as anti-inflammatory activity, cytokine suppression, and antifibrotic activity, are already approved. Ideally, one kinase inhibitor with optimal pharmacokinetic properties could be repurposed as a dual function therapeutic that could reduce infection through direct viral targeting and could also provide clinical benefit by suppressing disease symptoms. Alternatively, kinase inhibitors could be tested in combination with antiviral agents or other targeted therapies that show promise in clinical trials for COVID-19 to achieve greater efficacy than any one agent alone."}

{"project":"LitCovid-PubTator","denotations":[{"id":"345","span":{"begin":349,"end":357},"obj":"Disease"},{"id":"346","span":{"begin":605,"end":614},"obj":"Disease"},{"id":"347","span":{"begin":874,"end":882},"obj":"Disease"}],"attributes":[{"id":"A345","pred":"tao:has_database_id","subj":"345","obj":"MESH:C000657245"},{"id":"A346","pred":"tao:has_database_id","subj":"346","obj":"MESH:D007239"},{"id":"A347","pred":"tao:has_database_id","subj":"347","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Protein kinases have become an exceptionally important group of drug targets, accounting for 20-30% of the drug discovery programs of major pharmaceutical companies and are thus an opportune target. Many kinase inhibitors that have pharmacologic effects that may be beneficial in ameliorating the severe and potentially life-threatening symptoms of COVID-19, such as anti-inflammatory activity, cytokine suppression, and antifibrotic activity, are already approved. Ideally, one kinase inhibitor with optimal pharmacokinetic properties could be repurposed as a dual function therapeutic that could reduce infection through direct viral targeting and could also provide clinical benefit by suppressing disease symptoms. Alternatively, kinase inhibitors could be tested in combination with antiviral agents or other targeted therapies that show promise in clinical trials for COVID-19 to achieve greater efficacy than any one agent alone."}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T29","span":{"begin":204,"end":221},"obj":"http://purl.obolibrary.org/obo/GO_0033673"},{"id":"T30","span":{"begin":479,"end":495},"obj":"http://purl.obolibrary.org/obo/GO_0033673"},{"id":"T31","span":{"begin":734,"end":751},"obj":"http://purl.obolibrary.org/obo/GO_0033673"}],"text":"Protein kinases have become an exceptionally important group of drug targets, accounting for 20-30% of the drug discovery programs of major pharmaceutical companies and are thus an opportune target. Many kinase inhibitors that have pharmacologic effects that may be beneficial in ameliorating the severe and potentially life-threatening symptoms of COVID-19, such as anti-inflammatory activity, cytokine suppression, and antifibrotic activity, are already approved. Ideally, one kinase inhibitor with optimal pharmacokinetic properties could be repurposed as a dual function therapeutic that could reduce infection through direct viral targeting and could also provide clinical benefit by suppressing disease symptoms. Alternatively, kinase inhibitors could be tested in combination with antiviral agents or other targeted therapies that show promise in clinical trials for COVID-19 to achieve greater efficacy than any one agent alone."}

{"project":"LitCovid-sentences","denotations":[{"id":"T74","span":{"begin":0,"end":198},"obj":"Sentence"},{"id":"T75","span":{"begin":199,"end":465},"obj":"Sentence"},{"id":"T76","span":{"begin":466,"end":718},"obj":"Sentence"},{"id":"T77","span":{"begin":719,"end":936},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Protein kinases have become an exceptionally important group of drug targets, accounting for 20-30% of the drug discovery programs of major pharmaceutical companies and are thus an opportune target. Many kinase inhibitors that have pharmacologic effects that may be beneficial in ameliorating the severe and potentially life-threatening symptoms of COVID-19, such as anti-inflammatory activity, cytokine suppression, and antifibrotic activity, are already approved. Ideally, one kinase inhibitor with optimal pharmacokinetic properties could be repurposed as a dual function therapeutic that could reduce infection through direct viral targeting and could also provide clinical benefit by suppressing disease symptoms. Alternatively, kinase inhibitors could be tested in combination with antiviral agents or other targeted therapies that show promise in clinical trials for COVID-19 to achieve greater efficacy than any one agent alone."}

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T238","span":{"begin":64,"end":68},"obj":"CHEBI:23888;CHEBI:23888"},{"id":"T239","span":{"begin":107,"end":111},"obj":"CHEBI:23888;CHEBI:23888"},{"id":"T240","span":{"begin":140,"end":154},"obj":"CHEBI:52217;CHEBI:52217"},{"id":"T241","span":{"begin":211,"end":221},"obj":"CHEBI:35222;CHEBI:35222"},{"id":"T242","span":{"begin":232,"end":245},"obj":"CHEBI:52217;CHEBI:52217"},{"id":"T243","span":{"begin":320,"end":324},"obj":"UBERON:0000104"},{"id":"T244","span":{"begin":349,"end":357},"obj":"SP_7"},{"id":"T245","span":{"begin":486,"end":495},"obj":"CHEBI:35222;CHEBI:35222"},{"id":"T246","span":{"begin":509,"end":524},"obj":"CHEBI:52217;CHEBI:52217"},{"id":"T247","span":{"begin":630,"end":635},"obj":"NCBITaxon:10239"},{"id":"T248","span":{"begin":741,"end":751},"obj":"CHEBI:35222;CHEBI:35222"},{"id":"T249","span":{"begin":788,"end":804},"obj":"CHEBI:22587;CHEBI:22587"},{"id":"T250","span":{"begin":874,"end":882},"obj":"SP_7"}],"text":"Protein kinases have become an exceptionally important group of drug targets, accounting for 20-30% of the drug discovery programs of major pharmaceutical companies and are thus an opportune target. Many kinase inhibitors that have pharmacologic effects that may be beneficial in ameliorating the severe and potentially life-threatening symptoms of COVID-19, such as anti-inflammatory activity, cytokine suppression, and antifibrotic activity, are already approved. Ideally, one kinase inhibitor with optimal pharmacokinetic properties could be repurposed as a dual function therapeutic that could reduce infection through direct viral targeting and could also provide clinical benefit by suppressing disease symptoms. Alternatively, kinase inhibitors could be tested in combination with antiviral agents or other targeted therapies that show promise in clinical trials for COVID-19 to achieve greater efficacy than any one agent alone."}